A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Jazz Pharmaceuticals
Actuate Therapeutics Inc.
Northwestern University
Oslo University Hospital
Wake Forest University Health Sciences
Benaroya Research Institute
University of Miami
Vejle Hospital
University of Southern California
Seoul National University Bundang Hospital
Vejle Hospital
Eli Lilly and Company
Royal Marsden NHS Foundation Trust